$19.58
2.39% today
Nasdaq, Apr 04, 09:47 pm CET
ISIN
US4579852082
Symbol
IART

Integra LifeSciences Holdings Corporation Stock price

$20.06
-2.42 10.77% 1M
+3.11 18.35% 6M
-2.62 11.55% YTD
-13.84 40.83% 1Y
-44.48 68.92% 3Y
-21.36 51.57% 5Y
-8.09 28.74% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-1.72 7.90%
ISIN
US4579852082
Symbol
IART
Sector

Key metrics

Market capitalization $1.55b
Enterprise Value $3.26b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 130.61
EV/Sales (TTM) EV/Sales 2.02
P/S ratio (TTM) P/S ratio 0.96
P/B ratio (TTM) P/B ratio 1.00
Revenue growth (TTM) Revenue growth 4.47%
Revenue (TTM) Revenue $1.61b
EBIT (operating result TTM) EBIT $140.09m
Free Cash Flow (TTM) Free Cash Flow $24.96m
Cash position $273.57m
EPS (TTM) EPS $-0.09
P/E forward 21.49
P/S forward 0.92
EV/Sales forward 1.94
Short interest 5.98%
Show more

Is Integra LifeSciences Holdings Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Integra LifeSciences Holdings Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Integra LifeSciences Holdings Corporation forecast:

3x Buy
23%
6x Hold
46%
4x Sell
31%

Analyst Opinions

13 Analysts have issued a Integra LifeSciences Holdings Corporation forecast:

Buy
23%
Hold
46%
Sell
31%

Financial data from Integra LifeSciences Holdings Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
1,611 1,611
4% 4%
100%
- Direct Costs 687 687
13% 13%
43%
923 923
1% 1%
57%
- Selling and Administrative Expenses 556 556
9% 9%
35%
- Research and Development Expense 86 86
4% 4%
5%
281 281
18% 18%
17%
- Depreciation and Amortization 141 141
14% 14%
9%
EBIT (Operating Income) EBIT 140 140
36% 36%
9%
Net Profit -6.94 -6.94
110% 110%
0%

In millions USD.

Don't miss a Thing! We will send you all news about Integra LifeSciences Holdings Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Integra LifeSciences Holdings Corporation Stock News

Neutral
GlobeNewsWire
13 days ago
PHILADELPHIA, March 22, 2025 (GLOBE NEWSWIRE) -- Grabar Law Office is investigating whether the Board of Directors of Integra LifeSciences Holdings Corp. (NASDAQ: IART) breached their fiduciary duties owed to the Company.
Neutral
GlobeNewsWire
22 days ago
PRINCETON, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that Mojdeh Poul, chief executive officer and Lea Knight, chief financial officer will present at the 35th Annual Oppenheimer Healthcare MedTech & Services Conference on March 17, 2025 at 10:00am ET.
Neutral
Seeking Alpha
29 days ago
Integra LifeSciences had a rough 2024 as the company's quality control remediation efforts had a bigger than expected negative impact on results. Q4 '24 offered some stability with organic revenue growth and improved adjusted gross margins. 2025 guidance looks cautious, and a big cut to Q1 '25 expectations suggests that management may be pulling forward some of the lingering remediation costs.
More Integra LifeSciences Holdings Corporation News

Company Profile

Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Codman Specialty Surgical, and Orthopedics and Tissue Technologies segments. The Codman Specialty Surgical segment refers to the company's neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and precision tools and instruments business, which sells instrument patterns and surgical and lighting products to hospitals, surgery centers, and dental, podiatry, and veterinary offices. The Orthopedics and Tissue Technologies segment includes offerings such as skin and wound repair, bone and joint fixation implants in the upper and lower extremities, bone grafts, and nerve and tendon repair. The company was founded by Richard E. Caruso in 1989 and is headquartered in Princeton, NJ.

Head office United States
CEO Mojdeh Poul
Employees 4,396
Founded 1989
Website www.integralife.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today